What is the retatrutide dosing protocol?

Trial-Based Dosing Schedule

Lilly's released TRIUMPH-1 protocol used once-weekly subcutaneous retatrutide with stepwise escalation every four weeks. Target doses differed by arm:

• 4 mg target: started at 2 mg, then escalated to 4 mg
• 9 mg target: escalated through 2 mg, 4 mg, and 6 mg before 9 mg
• 12 mg target: escalated through 2 mg, 4 mg, 6 mg, and 9 mg before 12 mg

Earlier Phase 2 obesity testing used 1 mg, 4 mg, 8 mg, and 12 mg maintenance doses. Commercial dose strengths and titration have not been approved.

Why Slow Titration Is Necessary

Retatrutide is a triple agonist (GLP-1 + GIP + glucagon receptors). The combined receptor activation produces GI side effects that are:

• More intense than GLP-1 monotherapy at equivalent efficacy
• Dose-dependent in severity
• Tolerability-limiting at higher doses without titration

Slow titration allows receptor downregulation and physiological adaptation at each dose before escalating. Patients who titrate too quickly often experience severe nausea, vomiting, and early discontinuation.

Dose Ranges and Expected Outcomes

Low maintenance (4 mg weekly)

• Phase 2 obesity trial 48-week weight loss: 17.1% in the combined 4 mg group
• TRIUMPH-1 Phase 3 80-week weight loss: 19.0% using the efficacy estimand
• Fewer side effects
• Suitable for patients with modest weight loss goals or significant side effect issues

Middle maintenance (8 mg or 9 mg weekly, trial-dependent)

• Phase 2 obesity trial 48-week weight loss: 22.8% in the combined 8 mg group
• TRIUMPH-1 Phase 3 80-week weight loss: 25.9% at 9 mg using the efficacy estimand
• Moderate side effects
• Reasonable middle ground

Max maintenance (12 mg weekly)

• Phase 2 obesity trial 48-week weight loss: 24.2%
• TRIUMPH-1 Phase 3 80-week weight loss: 28.3% using the efficacy estimand
• Highest side effect burden
• For patients with significant weight loss goals who tolerate GI effects

Injection Technique

Subcutaneous injection, same as other GLP-1 class drugs:

• Rotate sites: abdomen, thigh, upper arm
• Use fresh needles each dose
• Inject at 90° angle through pinched skin
• Weekly on consistent day (accuracy within 2 days is fine)
• Pre-filled pen expected in commercial launch (similar to Wegovy, Zepbound)

Handling Dose Escalation Side Effects

If tolerating well at current dose

• Progress to next dose on schedule (every 4 weeks)
• Expect 1–2 weeks of adaptation at each new dose

If struggling at current dose

• Hold at current dose for additional 4 weeks before escalating
• Manage GI symptoms aggressively (see below)
• If still intolerable, stay at current dose or return to previous dose

GI symptom management during titration

• Eat smaller, more frequent meals
• Avoid high-fat and high-sugar meals
• Hydrate aggressively (2.5–3 L/day)
• Ginger tea or ginger supplements for nausea
• Over-the-counter anti-emetics (e.g., ondansetron) if prescribed
• Gentle walking aids gastric motility
• Avoid alcohol during titration

When to Consider NOT Escalating

• Adequate weight loss at current dose
• Severe persistent side effects
• Dehydration from vomiting or diarrhea
• Uncontrolled heart rate elevation
• Provider concerns about any other clinical marker

Maintenance Phase

Target dose reached

• Continue at maintenance dose indefinitely (or until goal reached)
• Monthly weight tracking
• Periodic lab monitoring
• Dose adjustments only as clinically indicated

Achieving goal weight

• Continue maintenance dose to hold weight
• Consider lower maintenance dose (e.g., 6 mg or 8 mg) if clinically appropriate
• Permanent cessation causes significant regain (see stopping article)

Comparison to Tirzepatide Titration

Tirzepatide and retatrutide have similar titration structures:

Tirzepatide

• 2.5 mg → 5 → 7.5 → 10 → 12.5 → 15 mg
• 4 weeks at each dose
• Max dose reached at week 20

Retatrutide

• 2 mg → 4 → 6 → 8 → 12 mg
• 4 weeks at each dose
• Max dose reached at week 16

Retatrutide's faster titration reflects its different receptor profile — triple agonism distributes receptor activation across GLP-1, GIP, and glucagon sites, potentially allowing steeper progression.

Lab Monitoring

Baseline

• Complete metabolic panel
• Lipid panel
• HbA1c
• Thyroid panel
• Liver function

Every 3 months during titration

• Basic metabolic panel
• HbA1c if diabetic
• Liver function

Annually at maintenance

• Complete metabolic panel
• Full lipid panel
• Age-appropriate screenings

Heart Rate Monitoring

Retatrutide, like other GLP-1 class drugs, can modestly increase resting heart rate — typically 5–10 bpm increase. Monitor:

• Baseline resting HR
• At each dose escalation
• Any symptoms of palpitations, chest discomfort, severe fatigue

Significant HR elevation (> 15 bpm increase, sustained) or new arrhythmia symptoms may warrant dose reduction or cardiology evaluation.

What Not to Do

• Don't escalate faster than every 4 weeks
• Don't skip doses to "reset" the drug
• Don't combine with other GLP-1 class drugs (semaglutide, tirzepatide)
• Don't titrate up through severe side effects hoping they'll resolve
• Don't stop cold from max dose — taper if discontinuing

When to Call Your Provider

• Severe persistent nausea or vomiting
• Unable to maintain hydration
• Severe abdominal pain
• Signs of pancreatitis (severe pain radiating to back)
• Chest pain or palpitations
• Signs of severe allergic reaction
• Significant unexpected weight loss beyond expected curve

Bottom Line

Retatrutide remains investigational, and there is no FDA-approved dosing protocol. Lilly's released TRIUMPH-1 protocol started participants at 2 mg once weekly and escalated every four weeks toward trial-specific target doses of 4 mg, 9 mg, or 12 mg. Commercial titration and maintenance doses will be set only if FDA approves retatrutide.

See the retatrutide guide. Related: side effects, vs tirzepatide.